GlassScriptPhysician profile
Kavitha Beedupalli
NPI 1568694321
$15,397.78
in general payments reported to CMS, 2019-2025
45 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $87.99 · 2021: $56.09 · 2022: $489 · 2023: $1,142 · 2024: $1,388 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,025 · Food and Beverage: $4,685 · Travel and Lodging: $1,771 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,025.00 |
| Food and Beverage | $4,685.41 |
| Travel and Lodging | $1,771.15 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $8,997.87 | 2022-2025 | Tecentriq, Tecentriq Hybreza, Alecensa |
| Intuitive Surgical, INC. | $1,280.05 | 2025 | |
| Daiichi Sankyo INC. | $649.04 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Astrazeneca Pharmaceuticals LP | $488.89 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Merck Sharp & Dohme LLC | $452.19 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Gilead Sciences, INC. | $341.62 | 2021-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $276.22 | 2020-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $252.43 | 2023-2025 | |
| Abbvie INC. | $244.53 | 2024-2025 | |
| Janssen Biotech, INC. | $192.95 | 2022-2025 | Rybrevant, Tecvayli, Darzalex |
| Bayer Healthcare Pharmaceuticals INC. | $184.39 | 2023-2025 | |
| Genentech, INC. | $163.86 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $154.83 | 2022-2025 | Libtayo |
| Lilly USA, LLC | $154.56 | 2019-2024 | Retevmo |
| Tempus Ai, INC | $120.87 | 2024-2025 | Xt Cdx |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kavitha Beedupalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.